BAY-1895344
Pwodwi detay
Tags pwodwi
| Gwosè pake | Disponibilite | Pri (USD) |
| 10 mg | Nan Stock | 210 |
| 100 mg | Nan Stock | 480 |
| 1g | Nan Stock | 950 |
Non Chimik:
(R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl)morfolin
Kòd SMILES:
CN1N=CC=C1C2=CC(N3[C@H](C)COCC3)=NC4=C(C5=CC=NN5)N=CC=C24.[H]Cl
Kòd InChi:
InChI=1S/C20H21N7O.ClH/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6- 21-20(19(14)24-18)16-4-7-22-25-16;/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25) ;1H/t13-;/m1./s1
InChi kle:
KWQNBYGUBHMRPY-BTQNPOSSSA-N
Mot:
1876467-74-1；CAS:1876467-74-1；CAS:1876467-74-1；BAY-1895344, BAY1895344, BAY 1895344
Solibilite:Soluble nan DMSO
Depo:0 - 4 ° C pou kout tèm (jou a semèn), oswa -20 ° C pou tèm long (mwa).
Deskripsyon:
BAY-1895344 se yon inibitè ATR selektif (ataxia-telangiectasia ak Rad3 ki gen rapò pwoteyin) ki anpeche pwopagasyon yon gwo spectre nan liy selil timè imen (medyan IC50 = 78 nM). BAY-1895344 devlope pou tretman pasyan ki gen timè solid ak lenfom avanse, epi li ap sibi yon faz I esè klinik sou sekirite ak tolerabilite pou pasyan kansè yo.
Sib: ATR